Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.61 |
| ▸ | MAPT | P10636 | 2/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.61 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.61 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.49 |
| ▸ | PRKDC | P78527 | 2/20 | 0.46 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.46 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.45 |
| ▸ | CDK9 | P50750 | 1/20 | 0.45 |
| ▸ | HASPIN | Q8TF76 | 1/20 | 0.45 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.44 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.44 |
| ▸ | PLG | P00747 | 1/20 | 0.43 |
| ▸ | PLAU | P00749 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9732348 | 0.88 | ALDH1A1 (0.56) | ALDH1A1KDM4EMAPTCYP1A2CYP2C19 | |
| SCHEMBL29957402 | 0.87 | ALDH1A1 (0.55) | ALDH1A1KDM4EMAPTCYP1A2CYP2C19 | |
| SCHEMBL31236307 | 0.87 | ALDH1A1 (0.55) | ALDH1A1KDM4EMAPTCYP1A2CYP2C19 | |
| SCHEMBL29952938 | 0.87 | ALDH1A1 (0.55) | ALDH1A1KDM4EMAPTCYP1A2CYP2C19 | |
| SCHEMBL29955479 | 0.87 | ALDH1A1 (0.55) | ALDH1A1KDM4EMAPTCYP1A2CYP2C19 | |
| SCHEMBL2536514 | 0.87 | ALDH1A1 (0.55) | ALDH1A1KDM4EMAPTCYP1A2CYP2C19 | |
| SCHEMBL2540187 | 0.87 | ALDH1A1 (0.55) | ALDH1A1KDM4EMAPTCYP1A2CYP2C19 | |
| SCHEMBL7835327 | 0.87 | ALDH1A1 (0.55) | ALDH1A1KDM4EMAPTCYP1A2CYP2C19 | |
| SCHEMBL29953126 | 0.87 | ALDH1A1 (0.55) | ALDH1A1KDM4EMAPTCYP1A2CYP2C19 | |
| SCHEMBL16727112 | 0.87 | ALDH1A1 (0.55) | ALDH1A1KDM4EMAPTCYP1A2CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| EP-1648867-B1 | PPAR ACTIVE COMPOUNDS | PLEXXIKON INC (US) | 2013-09-04 | — | — | EP | disclosed |
| US-8367828-B2 | PPAR active compounds | PLEXXIKON INC. (US) | 2013-02-05 | — | — | US | disclosed |
| US-20120122854-A1 | Carbocyclic Fused Cyclic Amines | BOEHRINGER MARKUS (CH) | 2012-05-17 | — | — | US | disclosed |
| US-20100210036-A1 | PPAR ACTIVE COMPOUNDS | PLEXXIKON, INC. | 2010-08-19 | — | — | US | disclosed |
| US-7723374-B2 | PPAR active compounds | PLEXXIKON, INC. (US) | 2010-05-25 | — | — | US | disclosed |
| US-7572806-B2 | PPAR active compounds | PLEXXIKON, INC. (US) | 2009-08-11 | — | — | US | disclosed |
| US-7491831-B2 | PPAR active compounds | PLEXXIKON, INC. (US) | 2009-02-17 | — | — | US | disclosed |
| US-7476746-B2 | PPAR active compounds | PLEXXIKON, INC. (US) | 2009-01-13 | — | — | US | disclosed |
| CN-101304989-A | Carbocyclic fused cyclic amines as inhibitors of the coagulation factor XA | HOFFMANN LA ROCHE (CH) | 2008-11-12 | — | — | CN | disclosed |
| US-20070112012-A1 | Carbocyclic fused cyclic amines | F. HOFFMANN-LA ROCHE AG (CH) | 2007-05-17 | — | — | US | disclosed |
| US-7202266-B2 | PPAR active compounds | PLEXXIKON, INC. (US) | 2007-04-10 | — | — | US | disclosed |
| EP-1648867-A1 | PPAR ACTIVE COMPOUNDS | PLEXXIKON, INC. (US) | 2006-04-26 | — | — | EP | disclosed |
| US-20050288354-A1 | PPAR active compounds | PLEXXIKON, INC. | 2005-12-29 | — | — | US | disclosed |
| US-20050038246-A1 | PPAR active compounds | PLEXXIKON, INC. | 2005-02-17 | — | — | US | disclosed |
| WO-2005009958-A1 | PPAR ACTIVE COMPOUNDS | PLEXXIKON, INC. (US) | 2005-02-03 | — | — | WO | disclosed |
| EP-0680950-B1 | PROPENONE DERIVATIVES | KYOWA HAKKO KOGYO KK (JP) | 2001-05-23 | — | — | EP | disclosed |
| US-5952355-A | 1-ETHER-SUBSTITUTED PHENYL-3-INDOL-3-YL-2-PROPEN-1-ONE DERIVATIVES; ANTITUMOR AND -CARCINOGENIC AGENTS; IMMUNOSUPPRESSANTS; AUTOIMMUNE DISEASES; SIDE EFFECT REDUCTION | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1999-09-14 | — | — | US | disclosed |
| EP-0680950-A1 | PROPENONE DERIVATIVE | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1995-11-08 | — | — | EP | disclosed |
| WO-1992007829-A1 | INDOLE-3-METHANAMINES USEFUL AS ANTI-DIABETIC, ANTI-OBESITY AND ANTI-ATHEROSCLEROTIC AGENTS | THE UPJOHN COMPANY (US) | 1992-05-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070112012-A1 | Carbocyclic fused cyclic amines | F12, F11, F2 | ALDH1A1 2287/4885KDM4E 2697/4885MAPT 4843/4885 |
| US-20050038246-A1 | PPAR active compounds | PPARG, PPARD, PPARA | ALDH1A1 1171/4885KDM4E 2954/4885MAPT 4598/4885 |
| US-20050288354-A1 | PPAR active compounds | PPARG, PPARD, PPARA | ALDH1A1 1171/4885KDM4E 2954/4885MAPT 4598/4885 |
| US-20120122854-A1 | Carbocyclic Fused Cyclic Amines | F12, F11, F2 | ALDH1A1 2287/4885KDM4E 2697/4885MAPT 4843/4885 |
| US-20100210036-A1 | PPAR ACTIVE COMPOUNDS | PPARG, PPARD, PPARA | ALDH1A1 1171/4885KDM4E 2954/4885MAPT 4598/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.